Seaport Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Seaport Therapeutics, Inc. (SPTX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $656.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-03
- Seaport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $325.00K, a 3.83% increase year-over-year.
- Seaport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $331.00K, a 18.64% increase year-over-year.
- Seaport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $313.00K.
- Seaport Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $279.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month |
|---|---|---|
| 2026-06-30 | $325.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $656.00K 10-Q · filed 2026-08-03 |
| 2026-03-31 | $331.00K 10-Q · filed 2026-06-08 | |
| 2025-06-30 | $313.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $592.00K 10-Q · filed 2026-08-03 |
| 2025-03-31 | $279.00K 10-Q · filed 2026-06-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |